Bessemer Group’s Puma Biotechnology PBYI Stock Holding History

Bessemer Group’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-24	Closed	–	–	1732
2019 Q3	$0	Buy	+24	New	+$259	﹤0.01%	1800

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bessemer Group's PBYI Position: Q4 2019 in Review

Bessemer Group sold out of Puma Biotechnology (PBYI) in Q4 2019, closing a stake of 24 shares.

Bessemer Group first reported a position in PBYI in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 133 funds tracked by Wall St. Rank hold PBYI as of Q4 2019.

Bessemer Group reported no remaining Puma Biotechnology position as of Q4 2019 after selling out during the quarter.
Bessemer Group sold 24 Puma Biotechnology shares in Q4 2019.
Bessemer Group first reported a position in Puma Biotechnology in Q3 2019 and held it in 1 quarter.
Bessemer Group's Puma Biotechnology position peaked at $0 in Q3 2019.
133 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2019.

Based on Bessemer Group's 13F filing for Q4 2019, filed 4 Feb 2020.